# Building a framework for adolescent and young adult transition of care for patients with neurofibromatosis type 1 and neurofibromatosis type 2-related schwannomatosis syndromes

**Authors:** Daniel Schwartzbaum, Christine Dinh, Nicholas A. Borja, Aditi Dhir, Jennifer Coto, Diane Jung, Michelle Pei, Olivia Kalmanson, Bradley Gampel

PMC · DOI: 10.3389/fonc.2026.1773687 · Frontiers in Oncology · 2026-03-02

## TL;DR

This paper outlines a framework to improve healthcare transitions for adolescents and young adults with neurofibromatosis type 1 and schwannomatosis.

## Contribution

The paper introduces a framework for adolescent and young adult transition of care specific to NF1 and NF2-SWN patients.

## Key findings

- NF1 and NF2-SWN patients require coordinated multidisciplinary care due to CNS tumors.
- AYA transition of care is under-researched for NF2-SWN patients.
- A structured HCT model can reduce care gaps and improve outcomes.

## Abstract

Neurofibromatosis type 1 (NF1) and Neurofibromatosis Type 2-Related Schwannomatosis (NF2-SWN) are the two most common genetic disorders that present with Central nervous system(CNS) tumors. Patients with NF1 and NF2-SWN typically present in childhood and are initially managed by pediatric subspecialties. As CNS tumors are the leading cause of pediatric cancer related death, managing these tumors in NF1 and NF2-SWN patients requires coordinated multidisciplinary life-long care. Adolescent and young adult (AYA) transition of care is a major opportunity for improvement in NF2 and NF2-SWN outcomes. While few small studies have focused on the NF1 population, there is minimal literature covering NF2-SWN AYA transition of care. Healthcare transition (HCT) is extremely complex for all chronic patients; however, these complexities are magnified in patients with NF1 and NF2-SWN. Having an AYA HCT model can decrease gaps in care and improve survival. We review the literature on NF1 and NF2-SWN transition of care and describe the necessary framework to establish a system to improve patient outcomes.

## Linked entities

- **Diseases:** Neurofibromatosis type 1 (MONDO:0018975)

## Full-text entities

- **Genes:** NF2 (NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor) [NCBI Gene 4771] {aka ACN, BANF, SCH, SWNV, merlin-1}, NF1 (neurofibromin 1) [NCBI Gene 4763] {aka NFNS, VRNF, WSS}
- **Diseases:** CNS tumors (MESH:D016543), NF2-SWN (MESH:C536641), death (MESH:D003643), genetic disorders (MESH:D030342), cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12990178/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12990178/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12990178/full.md

---
Source: https://tomesphere.com/paper/PMC12990178